Evaluation of elexacaftor–tezacaftor–ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial
Most Cited Paper
in Pediatric health and respiratory diseases
18 Months Post-Publication
Class of 2026
“Evaluation of elexacaftor–tezacaftor–ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
Elexacaftor/Tezacaftor/Ivacaftor · cystic fibrosis · CFTR N1303K · CFTR modulator · triple combination therapy · prospective trial · multicenter study · open-label trial · single-arm trial · rare CFTR mutation · nonsense mutation · lung function · Sweat chloride concentration · pulmonary exacerbations · quality of life assessment
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Pediatric health and respiratory diseases Papers, Class of 2026. https://pri.pepkio.com/top-papers/pediatric-health-and-respiratory-diseases/2026. Accessed 2026-08-20. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459